thought call
still wait pipelin larg scale reignit growth slow
although expect rel new ceo strategi take time materi
despit reach all-tim high hiv franchis under-perform consensu expect
driven mainli lower sale biktarvi indic view biktarvi great drug yet
valuat remain fulli realiz current valuat usual expect soft
start see subtl sign hiv franchis may strong expect
biktarvi project may inde high layer dynam
generic europ come us truvada gener expect late think
hiv may marque growth driver time continu believ biktarvi
prefer therapi physician indic numer check proprietari
survey could see downward revis estim reflect temper
expect descovi prep could help mitig impact truvada gener
like drive meaning upsidea prep penetr remain low market
balanc didnt see anyth significantli concern regard quarter howev
lack clear growth driver remain overarch theme support neutral thesi
oncolog focu howev remain cautiou expand invest
cell-therapi platform given poorer return invest kite
transact opportun outsid cell therapi target oncolog space small
molecul biolog could appropri focu given challeng face
car-t highlight call look pipelin asset look increment
updat filgotinib could deliv long-term growth reduc relianc hiv
franchis broadli warm ceo oday strategi far take
time deliv result saw signific chang manag recent deal
past month need see anoth deal help improv revenu earn
growth trajectori execut pipelin asset especi filgotinib could drive upsid near-
term think like take longer strateg move invigor stock
model updates/risk ep updat due revis revenu
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
inc biopharmaceut compani engag
research develop commerci medicin
area infecti diseas oncolog immunolog area
sky scenario model probabl success
yescarta expans well filgotinib also assum success
mid-stag nash asset exclud selonsertib maintain base
case third line yescarta hiv hcv sale
grey sky scenario model car-t platform
success beyond dlbcl filgotinib program delay fail
meet base-cas expect nash program fail
maintain base case third line yescarta hiv hcv sale
 close
pipelin updat regard filgotinib gilead submit regulatori file europ japan
remain track submit nda rheumatoid arthriti fda look
filgotinib compani expect data selction phase studi ulcer coliti
initi phase studi ankylos spondyl complet
enrol divers phase crohn diseas inflamm asset
inhibitor still evalu sjgren syndrom lupu
phase note indic previous list filgotinib
hiv franchis gilead expect file descovi prep base
earn report disclos galapago compani expect releas phase result
toledo program target still undisclos phase trial begin
model adjust made minor adjust core commerci portfolio
reflect current revenu trajectori decreas fy revenu estim
non-gaap ep increas
expect descovi base manag confid switch patient
truvada prep also lower biktarvi estim reflect slower uptak ou
final increas expens in-lin revis guidanc
figur model chang
gilead axicabtagen franchis ex product revenu includ glpg incom cs loss incom cs dilut cs charl martineau pm univers toronto octob
compani mention price
evan seigerman certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
